- Home
- RCKT vs VNDA Comparison
RCKT vs VNDA Comparison
Compare RCKT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | VNDA |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.6M | 361.4M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RCKT | VNDA |
|---|---|---|
| Price | $3.14 | $5.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $29.73 | $14.90 |
| AVG Volume (30 Days) | ★ 1.8M | 810.4K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $64.28 | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $2.53 | $4.14 |
| 52 Week High | $5.45 | $9.91 |
Technical Indicators
Market Signals| Indicator | RCKT | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 32.17 |
| Support Level | $2.95 | N/A |
| Resistance Level | $3.63 | $5.46 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 7.82 | 9.72 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.